{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-035974","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.816885+00:00","generated_at":"2026-05-31T10:45:28.219242+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocugen reports Q2 net loss $0.04/sh; advances OCU400 Phase 3 trial, raises $32.6M","bullets":["Net loss per share $0.04 in Q2 2024 versus $0.10 in Q2 2023; total operating expenses $16.6M, down from $24.0M.","Cash, equivalents, restricted cash $16.0M at June 30, 2024, down from $39.5M at Dec 31, 2023.","Subsequent to quarter end, closed public offering with net proceeds $32.6M, extending cash runway into Q3 2025.","Actively dosing patients in OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa; FDA approved expanded access program.","OCU410 Phase 2 initiated for geographic atrophy; OCU410ST high-dose dosing; OCU200 clinical hold discussions ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-035974","json":"https://secwatch.observer/filing/0001628280-24-035974.json","markdown":"https://secwatch.observer/filing/0001628280-24-035974.md","text":"https://secwatch.observer/filing/0001628280-24-035974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024035974/0001628280-24-035974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024035974/ocgn-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:45:28.219242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}